Comments
Aventis Pharma on Wednesday said its net profit surged over four-fold to Rs 104.9 crore in the fourth quarter ended December 31, 2010, over the same period last fiscal.
The company had posted a net profit of Rs 26 crore for the same period previous fiscal, Aventis Pharma said in a filing the Bombay Stock Exchange (BSE).
Total income of the company rose to Rs 307.2 crore for Q4 2010, compared to Rs 258.7 crore in the same period previous fiscal.
During the quarter, the company sold its entire share holding of 49 per cent of paid up share capital of the joint venture company Chiron Behring Vaccines Pvt Ltd (CBVPL) to Novartis Pharma AG for a consideration of Rs 100.75 crore.
The company’s board has recommended a final dividend of Rs 23 per share of Rs 10 for the year ended December 31, 2010.
The board has also approved a special one time dividend of Rs 28 per share of Rs 10, arising from the profit of the sale of the company’s shareholding in CBVPL.
For the year, the company posted a net profit of Rs 230.7 crore, compared to Rs 157.4 crore in the last fiscal, 2009.
Shares of Aventis Pharma today closed at Rs 1,846.95 on the BSE, up 1.20 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.